Rachel K. Anderson, PharmD, CSP

Therapy effectively treats cells harboring HR deficiencies, including those of specific types of ovarian, breast cancers.

PARP inhibitors in particular have changed the therapeutic landscape for EOC.

Numerous clinical trials are investigating the next generation of PARPi.

Trends in treatment development involve more targeted, safe, and efficacious therapies.

Rachel K. Anderson, PharmD, CSP, clinical program manager at Alliance Rx Walgreens Pharmacy, discusses the impact pharmacists have on the care journey for patients with multiple myeloma.

The disease can often be detected and managed early before a patient experiences signs or symptoms.

Biosimilars could save consumers more than $100 billion in the coming years.